Radiation may not help most early-stage breast cancer patients after mastectomy, a new American research has revealed.
The study, conducted by researchers at The University of Texas M. D. Anderson Cancer, found low present-day risk of recurrence following modern surgery and systemic therapy.
The research demonstrated that stage I and II patients, without spread to axillary lymph nodes or with 1-3 lymph nodes with metastasis who received surgery and adjuvant chemotherapy without radiation to the chestwall post-mastectomy, had a low overall risk of locoregional recurrences (LRR).
Henry Kuerer, senior author of the study and Training Program Director in M. D. Anderson's Department of Surgical Oncology, pointed out that 90 percent of patients diagnosed with node-positive disease will present with three or fewer nodes.
He said: "There is currently no question that radiotherapy after mastectomy is effective at decreasing the chances of LRR and is indicated in breast cancer patients with lymph node spread in greater than four nodes and where the risk of LRR is higher than 10 to 15 percent. However, the need for post-mastectomy radiation in early stage breast cancer patients has been a topic of great debate within the cancer community for decades."
In the 1990s, two landmark randomised trials showed a survival benefit for early stage breast cancer patients with lymph node metastases who received the therapy post-mastectomy, said Kuerer.
Subsequently, in 2005, a meta-analysis of randomised clinical trials that were conducted in the 1960s to 1980s demonstrated both a survival benefit, and a decreased risk of LRR for women with node positive breast cancer. These study findings shifted clinical practice: the National Comprehensive Cancer Network altered their medical guidelines in 2007 to suggest that stage I and II breast cancer patients with one to three lymph node metastases "strongly consider" radiation post-mastectomy.